DA-2811 vs Enavogliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

DA-2811

Marketed by Dong-A ST

Phase 2 in Type 2 Diabetessmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07239440 (registry estimate)

No aligned efficacy figure on record for this race.

Enavogliflozin · Envlo

Marketed by Daewoong Pharmaceutical and partners

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT04634500 · Phase 3 · completed

This Phase 3 trial randomly assigned 200 people with type 2 diabetes to enavogliflozin or to dapagliflozin, with participants and investigators unaware of assignment. It was designed to show enavogliflozin was not worse than dapagliflozin at lowering HbA1c over 24 weeks, within a margin of 0.35 percentage points. It met that test: HbA1c fell by 0.80 percentage points on enavogliflozin against 0.75 on dapagliflozin, a difference of 0.04 points (95% CI -0.21 to 0.12).

Next expected readout: December 2026 · NCT06399835 (registry estimate)

Reported efficacy

Change from baseline in HbA1c (at 24 weeks): Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35% (met)

Result source: NCT04634500

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDA-2811Enavogliflozin
HbA1c, change—Not reported-0.8% vs -0.8%avs dapagliflozinwk 24NCT04634500
Body weight, change (kg)—Not reported—Not posted · NCT05376969
HbA1c below 7%—Not reported—Not posted · NCT05376969
Fasting plasma glucose, change—Not reported—Not posted · NCT05376969
3-point MACE (% with event)—Not reported—Not posted · NCT05376969

HbA1c, change

DA-2811
—Not reported
Enavogliflozin
-0.8% vs -0.8%avs dapagliflozinwk 24NCT04634500

Body weight, change (kg)

DA-2811
—Not reported
Enavogliflozin
—Not posted · NCT05376969

HbA1c below 7%

DA-2811
—Not reported
Enavogliflozin
—Not posted · NCT05376969

Fasting plasma glucose, change

DA-2811
—Not reported
Enavogliflozin
—Not posted · NCT05376969

3-point MACE (% with event)

DA-2811
—Not reported
Enavogliflozin
—Not posted · NCT05376969
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

DA-2811: no structured comparison results are available for Type 2 Diabetes.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Enavogliflozin

HbA1c -0.8% vs -0.75% dapagliflozin @ 24wk
absolute change · percentage points
NCT04634500 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DA-2811's landscape · Enavogliflozin's landscape